Resection vs. transplantation for hepatocellular carcinoma: a never ending challenge
- PMID: 37351126
- PMCID: PMC10282667
- DOI: 10.21037/hbsn-23-131
Resection vs. transplantation for hepatocellular carcinoma: a never ending challenge
Keywords: Hepatocellular carcinoma (HCC); liver resection; liver transplantation (LT); recurrence; survival.
Conflict of interest statement
Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-23-131/coif). JFF reports lecture fees from Bayer and AstraZeneca and consultancy fees from AstraZeneca. JB reports grant support from CIBERehd which is funded by the Instituto de Salud Carlos III and educational grants from Bayer, consultancy fees from Arqule, Bayer, Novartis, BMS, BTG-Biocompatibles, Eisai, Kowa, Terumo, Gilead, Bio-Alliance, Roche, AbbVie, Merck, Sirtex, Sanofi, Ipsen, Astra-Medimmune, Incyte, Quirem, Adaptimmune, Lilly, and lecture fees from Bayer, BTG-Biocompatibles, Terumo, Roche, Sirtex, and Ipsen. The authors have no other conflicts of interest to declare.
Comment on
-
Liver resection versus liver transplantation for hepatocellular carcinoma within Milan criteria: a meta-analysis of 18,421 patients.Hepatobiliary Surg Nutr. 2022 Feb;11(1):78-93. doi: 10.21037/hbsn-21-350. Hepatobiliary Surg Nutr. 2022. PMID: 35284509 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources